keyword
MENU ▼
Read by QxMD icon Read
search

Multiple sclerosis food

keyword
https://read.qxmd.com/read/30706431/real-world-characterization-of-dimethyl-fumarate-related-gastrointestinal-events-in-multiple-sclerosis-management-strategies-to-improve-persistence-on-treatment-and-patient-outcomes
#1
Jinny Min, Stanley Cohan, Enrique Alvarez, Jacob Sloane, J Theodore Phillips, Anneke van der Walt, Irene Koulinska, Fang Fang, Catherine Miller, Andrew Chan
INTRODUCTION: Delayed-release dimethyl fumarate (DMF) is an effective treatment for multiple sclerosis (MS). Some patients experience gastrointestinal (GI) adverse events (AEs) that may lead to premature DMF discontinuation. This study characterized the impact of site-specific GI management strategies on the occurrence of GI events and discontinuation patterns. METHODS: Data on GI events and DMF persistence were retrospectively abstracted from medical records of patients treated with DMF in routine medical practice in the EFFECT study (NCT02776072)...
January 31, 2019: Neurology and Therapy
https://read.qxmd.com/read/30677733/systematic-review-and-network-meta-analysis-comparing-ocrelizumab-with-other-treatments-for-relapsing-multiple-sclerosis
#2
Rachael McCool, Katy Wilson, Mick Arber, Kelly Fleetwood, Sydney Toupin, Howard Thom, Iain Bennett, Susan Edwards
BACKGROUND: Ocrelizumab was approved for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS) by the US Food and Drug Administration in March 2017 and by the European Medicines Agency in January 2018. These approvals were based on two pivotal randomized controlled trials (RCTs), OPERA I and OPERA II, comparing ocrelizumab 600 mg with an active comparator, interferon β-1a 44 μg (Rebif), and the first trial with positive results in patients with PPMS, which compared ocrelizumab with placebo...
January 2, 2019: Multiple Sclerosis and related Disorders
https://read.qxmd.com/read/30630959/food-allergies-and-multiple-sclerosis
#3
Mauricio Franco Farez
No abstract text is available yet for this article.
January 10, 2019: Journal of Neurology, Neurosurgery, and Psychiatry
https://read.qxmd.com/read/30626570/diet-and-multiple-sclerosis-scoping-review-of-web-based-recommendations
#4
REVIEW
Jeffrey M Beckett, Marie-Louise Bird, Jane K Pittaway, Kiran Dk Ahuja
BACKGROUND: There is currently no scientific evidence supporting the use of specific diets in the management of multiple sclerosis (MS); the strongest dietary associations are observed with vitamin D and omega-3 fatty acid supplementation. Despite this, there are many websites that provide advice or suggestions about using various dietary approaches to control symptoms or disease progression. OBJECTIVE: The objective of this study was to assess the dietary advice for the symptomatic management of MS available on the internet...
January 9, 2019: Interactive Journal of Medical Research
https://read.qxmd.com/read/30625282/fingolimod-lessons-learned-and-new-opportunities-for-treating-multiple-sclerosis-and-other-disorders
#5
Jerold Chun, Yasuyuki Kihara, Deepa Jonnalagadda, Victoria A Blaho
Fingolimod (FTY720, Gilenya) was the first US Food and Drug Administration-approved oral therapy for relapsing forms of multiple sclerosis (MS). Research on modified fungal metabolites converged with basic science studies that had identified lysophospholipid (LP) sphingosine 1-phosphate (S1P) receptors, providing mechanistic insights on fingolimod while validating LP receptors as drug targets. Mechanism of action (MOA) studies identified receptor-mediated processes involving the immune system and the central nervous system (CNS)...
January 6, 2019: Annual Review of Pharmacology and Toxicology
https://read.qxmd.com/read/30615021/assessment-of-use-of-combined-dextromethorphan-and-quinidine-in-patients-with-dementia-or-parkinson-disease-after-us-food-and-drug-administration-approval-for-pseudobulbar-affect
#6
Michael Fralick, Chana A Sacks, Aaron S Kesselheim
Importance: In 2010, the US Food and Drug Administration (FDA) approved a combination of dextromethorphan hydrobromide and quinidine sulfate for the treatment of pseudobulbar affect after studies in patients with amyotrophic lateral sclerosis (ALS) or multiple sclerosis (MS). This medication, however, may be commonly prescribed in patients with dementia and/or Parkinson disease (PD). Objective: To investigate the prescribing patterns of dextromethorphan-quinidine, including trends in associated costs...
January 7, 2019: JAMA Internal Medicine
https://read.qxmd.com/read/30566030/dalfampridine-benefits-ambulation-but-not-cognition-in-multiple-sclerosis
#7
Nikhil Satchidanand, Allison Drake, A Smerbeck, David Hojnacki, Channa Kolb, Kara Patrick, Bianca Weinstock-Guttman, Robert Motl, Ralph Hb Benedict
BACKGROUND: Impaired cognition and ambulation are common in multiple sclerosis (MS). Dalfampridine is the first Food and Drug Administration (FDA)-approved medication to treat impaired ambulation in MS. Dalfampridine may benefit patients with cognitive impairment, given its effects on saltatory conduction and the association between cognitive and motor function. OBJECTIVE: To examine the effects of dalfampridine on cognition in MS. To determine if the anticipated improved cognition is grounded in dalfampridine's effects on ambulation...
December 19, 2018: Multiple Sclerosis: Clinical and Laboratory Research
https://read.qxmd.com/read/30563943/food-allergies-are-associated-with-increased-disease-activity-in-multiple-sclerosis
#8
Rami Fakih, Camilo Diaz-Cruz, Alicia S Chua, Cindy Gonzalez, Brian C Healy, Neda Sattarnezhad, Bonnie I Glanz, Howard L Weiner, Tanuja Chitnis
OBJECTIVE: The association between allergy and multiple sclerosis (MS) is still unclear. In our study, we assessed the association between a self-reported history of allergic conditions with MS clinical and MRI disease activity. METHODS: A subset of 1349 patients enrolled in the Comprehensive Longitudinal Investigation of Multiple Sclerosis at the Brigham and Women's Hospital (CLIMB) study completed a self-administered questionnaire on environmental, food and drug allergies...
December 18, 2018: Journal of Neurology, Neurosurgery, and Psychiatry
https://read.qxmd.com/read/30544079/cryptococcal-meningitis-in-a-multiple-sclerosis-patient-treated-with-fingolimod-a-case-report-and-review-of-imaging-findings
#9
Insun Chong, Kevin Yuqi Wang, Christie M Lincoln
Fingolimod is an oral medication approved by the Food and Drug Administration in 2009 for the treatment of relapsing remitting multiple sclerosis (RRMS). Initial clinical trials did not show a significantly increased rate of serious infections with fingolimod therapy. However, a mildly increased risk of less serious infections, such as varicella zoster virus and herpes simplex virus, was reported. Recently, however, several instances of serious opportunistic infections have been reported. In the years following approval of fingolimod for use in multiple sclerosis (MS), seven cases of cryptococcal meningitis in patients undergoing treatment have been described in the literature...
November 14, 2018: Clinical Imaging
https://read.qxmd.com/read/30504122/effect-of-dietary-additives-on-intestinal-permeability-in-both-drosophila-and-a-human-cell-co-culture
#10
Matthew T Pereira, Mridu Malik, Jillian A Nostro, Gretchen J Mahler, Laura Palanker Musselman
Increased intestinal barrier permeability has been correlated with aging and disease, including type 2 diabetes, Crohn's disease, celiac disease, multiple sclerosis and irritable bowel syndrome. The prevalence of these ailments has risen together with an increase in industrial food processing and food additive consumption. Additives, including sugar, metal oxide nanoparticles, surfactants and sodium chloride, have all been suggested to increase intestinal permeability. We used two complementary model systems to examine the effects of food additives on gut barrier function: a Drosophila in vivo model and an in vitro human cell co-culture model...
November 28, 2018: Disease Models & Mechanisms
https://read.qxmd.com/read/30416122/-b-cell-depletion-therapy-in-multiple-sclerosis
#11
Yusei Miyazaki, Masaaki Niino
Since the initial observation of increased immunoglobulin concentrations in the cerebrospinal fluid of patients with multiple sclerosis (MS) in the 1940s, B cells have been considered to participate in the pathology of MS through the production of autoantibodies reactive against central nervous system antigens. However, it is now recognized that B cells contribute to MS relapses by antibody-independent activities, including presenting antigens to T cells and releasing pro-inflammatory cytokines. In addition, the recent identification of B cell-rich follicle-like structures in the meninges of patients with MS suggests that pathogenic roles of B cells also exist at the progressive phase...
November 2018: Brain and Nerve, Shinkei Kenkyū No Shinpo
https://read.qxmd.com/read/30375258/understanding-barriers-enablers-and-long-term-adherence-to-a-health-behavior-intervention-in-people-with-multiple-sclerosis
#12
Emma Barnard, Chelsea R Brown, Tracey J Weiland, George A Jelinek, Claudia H Marck
BACKGROUND: The optimal management strategy for multiple sclerosis (MS), and many other chronic diseases, likely involves health behavior modification. Multimodal behavioral interventions may be most effective, but little is known about long-term adherence in people with MS. METHODS: This qualitative study assessed barriers and enablers to long-term adherence by people with MS who self-selected for a 5-day health behavior intervention 3-5 years prior. Thirteen women and five men participated in semi-structured phone interviews, which were transcribed and thematically analyzed...
October 30, 2018: Disability and Rehabilitation
https://read.qxmd.com/read/30357921/what-can-primary-immunodeficiencies-teach-us-about-th9-cell-differentiation-function
#13
Lisa Worley, Stuart G Tangye, Cindy S Ma
Interleukin-9 (IL-9) producing CD4+ Th9 cells are a unique subset of effector cells involved in both health and disease. Th9 cells have been associated with protective immunity during parasitic infections with helminths, protozoans and extracellular pathogens, but implicated in disease states such as allergic asthma, atopic dermatitis, food allergy and autoimmune conditions including multiple sclerosis and ulcerative colitis. Here, we review the cytokine signalling pathways and downstream transcription factors required for IL-9 expression and how human primary immunodeficiencies due to monogenic mutations can help elucidate the complex requirements for human Th9 cell differentiation...
October 25, 2018: Immunology and Cell Biology
https://read.qxmd.com/read/30351179/diet-quality-and-risk-of-multiple-sclerosis-in-two-cohorts-of-us-women
#14
Dalia L Rotstein, Marianna Cortese, Teresa T Fung, Tanuja Chitnis, Alberto Ascherio, Kassandra L Munger
OBJECTIVE: To determine the association between measures of overall diet quality (dietary indices/patterns) and risk of multiple sclerosis (MS). METHODS: Over 185,000 women in the Nurses' Health Study (NHS) and Nurses' Health Study II (NHSII) completed semiquantitative food frequency questionnaires every 4 years. There were 480 MS incident cases. Diet quality was assessed using the Alternative Healthy Eating Index-2010 (AHEI-2010), Alternate Mediterranean Diet (aMED) index, and Dietary Approaches to Stop Hypertension (DASH) index...
October 23, 2018: Multiple Sclerosis: Clinical and Laboratory Research
https://read.qxmd.com/read/30333163/use-of-newer-disease-modifying-therapies-in-pediatric-multiple-sclerosis-in-the-us
#15
Kristen M Krysko, Jennifer Graves, Mary Rensel, Bianca Weinstock-Guttman, Gregory Aaen, Leslie Benson, Tanuja Chitnis, Mark Gorman, Manu Goyal, Lauren Krupp, Timothy Lotze, Soe Mar, Moses Rodriguez, John Rose, Michael Waltz, T Charles Casper, Emmanuelle Waubant
OBJECTIVE: To characterize the use and safety of newer disease-modifying therapies (DMTs) in children with multiple sclerosis (MS) and clinically isolated syndrome (CIS) treated under 18 years of age. METHODS: This is a cohort study including children with MS or CIS followed at 12 outpatient practices participating in the US Network of Pediatric MS Centers. DMT use, including duration, dose, and side effects, was analyzed. Newer DMTs were defined as agents receiving Food and Drug Administration approval or with increased use in adult MS after 2005...
November 6, 2018: Neurology
https://read.qxmd.com/read/30319182/neurochemical-and-behavioral-dysfunctions-in-pesticide-exposed-farm-workers-a-clinical-outcome
#16
REVIEW
Rajesh Kumar Kori, Manish Kumar Singh, Abhishek Kumar Jain, Rajesh Singh Yadav
The problem of pesticides is not new and its exposure to human due to indiscriminate use is largely associated with the health related problems including neurotoxicological alterations. High levels of pesticide residues and their metabolites in the dietary constituents, food materials, maternal blood, cord blood, placenta breast milk have been reported and linked to alterations in birth weight, crown heel length, head circumference, mid-arm circumference and ponderal index of the neonates. Epidemiological studies have suggested that exposure of pesticide to human could be a significant risk factor for neurological disorders, including Parkinson's disease, Alzheimer's disease and multiple sclerosis...
October 2018: Indian Journal of Clinical Biochemistry: IJCB
https://read.qxmd.com/read/30275700/analysis-nutrition-and-health-benefits-of-tryptophan
#17
REVIEW
Mendel Friedman
Tryptophan is an essential plant-derived amino acid that is needed for the in vivo biosynthesis of proteins. After consumption, it is metabolically transformed to bioactive metabolites, including serotonin, melatonin, kynurenine, and the vitamin niacin (nicotinamide). This brief integrated overview surveys and interprets our current knowledge of the reported multiple analytical methods for free and protein-bound tryptophan in pure proteins, protein-containing foods, and in human fluids and tissues, the nutritional significance of l-tryptophan and its isomer d-tryptophan in fortified infant foods and corn tortillas as well the possible function of tryptophan in the diagnosis and mitigation of multiple human diseases...
2018: International Journal of Tryptophan Research: IJTR
https://read.qxmd.com/read/30215191/association-between-exposure-to-heavy-metals-and-systemic-sclerosis-the-levels-of-al-cd-hg-and-pb-in-blood-and-urine-of-patients
#18
Giovanni Forte, Carlo Fadda, Beatrice Bocca, Gian Luca Erre, Giuseppe Passiu, Roberto Madeddu
Systemic sclerosis (SSc) is a multisystem connective tissue disease; exogenous factors-including heavy metals-may have a role in the disease pathogenesis. In this context, a study on the quantification of Al, Cd, Hg, and Pb in blood and urine of 27 SSc patients and 30 controls was carried out. Main findings were that Al was significantly depleted in blood and increased in urine of SSc patients respect to controls; and Pb was found slightly increased in blood and significantly decreased in SSc group. In addition, higher Hg levels in urine were found in SSc subjects with the higher severity of the disease...
September 13, 2018: Biological Trace Element Research
https://read.qxmd.com/read/30170268/is-there-an-effect-of-dietary-intake-on-ms-related-fatigue-a-systematic-literature-review
#19
REVIEW
Uwe Martin Pommerich, John Brincks, Marie Ernst Christensen
BACKGROUND: Fatigue is considered the most common symptom of persons with multiple sclerosis MS (pwMS), occurring in up to 90% of the patients at some point with two-thirds of pwMS experience fatigue as their most disturbing symptom. Pharmacological treatment options for MS-related fatigue show only limited and contradicting results. Consequently, many pwMS search for alternative options to control the symptom. A considerable interest in dietary interventions as a means of MS symptom management has advanced in the MS community...
October 2018: Multiple Sclerosis and related Disorders
https://read.qxmd.com/read/30136689/release-of-interleukin-10-and-neurotrophic-factors-in-the-choroid-plexus-possible-inductors-of-neurogenesis-following-copolymer-1-immunization-after-cerebral-ischemia
#20
Yolanda Cruz, Edna E García, Jessica V Gálvez, Stella V Arias-Santiago, Horacio G Carvajal, Raúl Silva-García, Herlinda Bonilla-Jaime, Julio Rojas-Castañeda, Antonio Ibarra
Copolymer-1 (Cop-1) is a peptide with immunomodulatory properties, approved by the Food and Drug Administration of United States in the treatment of multiple sclerosis. Cop-1 has been shown to exert neuroprotective effects and induce neurogenesis in cerebral ischemia models. Nevertheless, the mechanism involved in the neurogenic action of this compound remains unknown. The choroid plexus (CP) is a network of cells that constitute the interphase between the immune and central nervous systems, with the ability to mediate neurogenesis through the release of cytokines and growth factors...
October 2018: Neural Regeneration Research
keyword
keyword
163119
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"